RxDoctor Payments Data

Dan Fintel, MD

Cardiovascular Disease · Chicago, ILNPI 1992740328

Payments from drug & device makers

$118,807in general payments, 2019–2025

Across 336 payments — averaging $353.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$89K
  • Pfizer$12K
  • Sanofi-aventis U.S. LLC$7K
  • AstraZeneca$3K
  • Novartis$1K
  • GSK$1K
  • plus $5K from 20 others

What the payments were for

  • Consulting fees$4990%
  • Speaking & faculty fees$103,49587%
  • Travel & lodging$4,0973%
  • Food & beverage$10,6469%
  • Education$700%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$118,807 in reported general payments places this provider in the 90th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$161,300
Medicare patients
1,508
Services billed
5,116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban113$173,966
EntrestoSacubitril/Valsartan85$111,936
XareltoRivaroxaban46$44,155
JardianceEmpagliflozin33$38,588
FarxigaDapagliflozin Propanediol33$29,879
BrilintaTicagrelor19$23,992
Metoprolol Succinate400$6,325
Atorvastatin Calcium517$6,286
Ezetimibe174$5,083
Ranolazine ErRanolazine27$4,295
Rosuvastatin Calcium213$3,800
Losartan Potassium180$2,697
Amlodipine Besylate205$2,009
Candesartan Cilexetil14$1,880
Diltiazem 24hr Er (Cd)Diltiazem Hcl50$1,872

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11,719$173,966113 claims
NovartisEntresto$1,421$111,93685 claims
AstraZenecaFarxiga, Brilinta$3,488$53,87152 claims
Johnson & JohnsonXarelto$89,167$44,15546 claims
Boehringer IngelheimJardiance$559$38,58833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →